Neurogene Reports Third-Quarter 2026 Financial Results and Recent Updates
Neurogene announced its third-quarter 2026 financial results and highlighted recent corporate updates.
Story updates
12:30:47 PM UTC
SquawkNews
Neurogene announced third quarter 2026 financial results. It expects topline data from the Embolden registrational trial in the second half of 2027 and says PPQ runs remain on track for completion this year.Material DetailsContext by AI AnalystThis is a clinical-stage company advancing NGN-401 towa…
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2026 financial results and highlighted recent corporate updates.“During the third quarter, we contin…